Kuwait Pharmaceuticals and Healtcare Report Q2 2008

Publication Date	April 2008
Publisher	Business Monitor
Product Type	Report
Pages	65
ISBN Number	1748-1996
Product Code	BMI01157

Price

£425.00
approximately: $750 | €539

PDF immediate delivery

Order above formats by FAX

Summary

Kuwait's pharmaceutical market was estimated to be worth US$332.8mn in 2007 and should grow at around 10% year-on-year (y-o-y) to reach a value of US$550.6mn by 2012. Market growth, as in other Gulf Co-operation Council (GCC) states, should be underpinned by an expanding population and an epidemiological shift towards chronic non-communicable diseases. Kuwait's oil reserves should continue to underpin economic growth through the forecast period, ensuring per capita incomes continue to grow.

As in other gulf states, a trend for more cost-conscious government health policy is emerging that may serve to dampen pharmaceutical growth, particularly in the patented drug sector. However, the private sector, which has grown in strength over the past few years, should take a more prominent role in its place.

Government policy, combined with increased awareness of the bioequivalence of generics should allow the generics market to grow strongly over the forecast period, beating the overall drug market growth trend to account for 18% of the total market by 2012. This growth should provide an opportunity for the country's small domestic manufacturing sector, which consists of state-owned Kepisco. However, due to ever increasing GCC integration, BMI expects imports to account for most new sales. The GCC common market should allow gulf drugmakers in particular to take advantage.

In BMI's updated Business Environment Ratings, Kuwait received a score of 52, down three points from Q108. The lower score resulted in a fall of two places in the Middle East and Africa (MEA) rankings table to fifth position out of 14 markets surveyed. Our assessment was downgraded after new data which suggested that Kuwait's pharmaceutical market had grown less quickly than expected in recent years. In terms of market risk, our assessment of Kuwait's business environment remains unchanged.

Healthcare is provided largely free of charge to Kuwaiti citizens. However, an aging population with a significant chronic disease burden is expected to force the government to avail itself of some of the financial responsibilities.

Content

Executive Summary
- SWOT Analysis
- Kuwait Pharmaceuticals And Healthcare Industry SWOT
- Kuwait Political SWOT
- Kuwait Economic SWOT
- Kuwait Business Environment SWOT
- Pharmaceutical Business Environment Ratings
- Limits Of Potential Returns
- Risks To Realisation Of Returns
- Kuwait - Market Summ11
- Regulatory Regime
- Foreign Direct Investment Regulations
- Intellectual Property Regime
- IP Shortcomings
- Pricing And Reimbursement Regime
- Public Procurement Of Medicines
- Regional Harmonisation
- Free Trade Agreements
- Industry Developments
- Health Status
- Recent Public Health Developments
- Healthcare Sector
- Primary Care
- Secondary Care
- Recent Healthcare Sector Developments
- Healthcare Insurance
- Healthcare Reforms
- Regional Developments
- International Collaboration
- Pharmaceutical Sector
- Research And Development
- Biotechnology Sector
- Industry Forecast Scenario
- Overall Market Forecasts
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Prescription Market Forecast
- OTC Market Forecast
- Generics And Patented Market Forecast
- Export/Import Market Forecasts
- Other Healthcare Data
- Key Risks To BMI Forecasts
- Competitive Landscape
- Company Profiles
- Multinationals
- Novartis
- Sanofi-Aventis
- Pfizer
- GlaxoSmithKline
- Merck & Co
- Johnson & Johnson
- Indigenous Players
- Advanced Technology Company
- Bader Sultan & Bros
- Safwan Trading And Contracting Company
- BMI Forecast Modelling
- How We Generate Our Industry Forecasts
- Pharmaceutical Industry
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Weighting
- Sources
List of Tables
- Table: Middle East And Africa Pharmaceutical Business Environment Ratings
- Table: USTR 'Special 301' Report
- Table: Kuwait's Drug Expenditure, 2006-2012
- Table: Kuwait's Health Expenditure, 2006-2012
- Table: Kuwait - Economic Activity
- Table: Kuwait Prescription Market, 2006-2012 (US$mn unless otherwise stated)
- Table: Kuwait's OTC Market, 2006-2012 (US$mn unless otherwise stated)
- Table: Kuwait's Generics And Patented Market Indicators, 2006-2012
- Table: India's Export Of Pharmaceutical Products To The GCC Countries (US$mn)
- Table: Kuwait's Pharmaceutical Trade Indicators, 2006-2012 (US$mn unless otherwise stated)
- Table: Kuwait - Other Healthcare Indicators, 2006-2012
- Table: Pharmaceutical Business Environment Indicators
- Table: Weighting Of Components

About this Product

Delivery Details

PDF:Immediate delivery

Ask a question about this product?

Need help finding the right product?

Product features / use

Scope	Expert Insight/Opinion
Level	General Industry Strategies
Data	Detailed Market Forecasts
Profiles	Profiles of Key Companies
Features	Contains SWOT Analysis
Extra Info	Consumer Trends Highlighted